Clinical Trial Update: Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of Axicabtagene ciloleucel in relapsed or refractory primary mediastinal B-cell lymphoma has been terminated; the update does not provide results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mediastinal B-cell Lymphoma

Drugs mentioned

• Axicabtagene ciloleucel (axicabtagene ciloleucel)

Snippet

Sponsor: Universität Münster | Conditions: B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent | Phase 2 | Status: TERMINATED